PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gutgesell, R.M. ; Nogueiras, R.* ; Tschöp, M.H. ; Müller, T.D.

Dual and triple incretin-based co-agonists: Novel therapeutics for obesity and diabetes.

Diabetes Ther. 15, 1069-1084 (2024)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The discovery of long-acting incretin receptor agonists represents a major stride forward in tackling the dual epidemic of obesity and diabetes. Here we outline the evolution of incretin-based pharmacotherapy, from exendin-4 to the discovery of the multi-incretin hormone receptor agonists that look set to be our next step toward curing diabetes and obesity. We discuss the multiagonists currently in clinical trials and the improvement in efficacy each new generation of these drugs bring. The success of these agents in preclinical models and clinical trials suggests a promising future for multiagonists in the treatment of metabolic diseases, with the most recent glucose-dependent insulinotropic peptide receptor:glucagon-like peptide 1 receptor:glucagon receptor (GIPR:GLP-1R:GCGR) triagonists rivaling the efficacy of bariatric surgery. However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gut-brain communication can be leveraged to achieve sustained body weight loss without adverse effects.
Impact Factor
Scopus SNIP
Altmetric
2.800
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Diabetes ; Dual-agonist ; Gip ; Glp-1 ; Glucagon ; Incretin ; Obesity ; Triagonist; Dependent Insulinotropic Polypeptide; Glucagon-like Peptide-1; Gastric-inhibitory Polypeptide; Receptor Agonist; Double-blind; Glycemic Control; Cardiovascular Outcomes; Exenatide Exendin-4; Recombinant Leptin; Lipoprotein-lipase
Sprache englisch
Veröffentlichungsjahr 2024
HGF-Berichtsjahr 2024
ISSN (print) / ISBN 1869-6961
e-ISSN 1869-6953
Zeitschrift Diabetes Therapy
Quellenangaben Band: 15, Heft: 5, Seiten: 1069-1084 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Diabetes and Obesity (IDO)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-501900-221
G-502200-001
Förderungen European Research Council
DOI 10.1007/s13300-024-01566-x
WOS ID 001197097800001
Scopus ID 85190264142
PubMed ID 38573467
Erfassungsdatum 2024-06-03
[➜Korrektur melden]